ReviewExpert opinion on investigational drugs2009
The development of antibody-IL-2 based immunotherapy with hu14.18-IL2 (EMD-273063) in melanoma and neuroblastoma.
Review in Expert opinion on investigational drugs, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 36 citations in OpenAlex.
- Cytokine fusion proteins for solid tumor therapy: mechanistic insights and clinical advances.Journal of hematology & oncology · 2026Review
- Bone marrow aspirate Cit-H3 was identified as a novel biomarker of minimal residual disease in neuroblastoma.BMC cancer · 2025Article
- A Multi-Color Flow Cytometric Assay for Quantifying Dinutuximab Binding to Neuroblastoma Cells in Tumor, Bone Marrow, and Blood.Journal of clinical medicine · 2023Article
- Stimulation of natural killer cells with small molecule inhibitors of CD38 for the treatment of neuroblastoma.Chemical science · 2023Article
- Pharmacogenetics in Neuroblastoma: What Can Already Be Clinically Implemented and What Is Coming Next?International journal of molecular sciences · 2021Review
- Monoclonal Antibody Therapies for High Risk Neuroblastoma.Biologics : targets & therapy · 2021Review
- Trial watch: intratumoral immunotherapy.Oncoimmunology · 2021Review
- Medical Options for the Adjuvant Treatment and Management of Pediatric Melanoma.Paediatric drugs · 2019Review
- Spotlight on dinutuximab in the treatment of high-risk neuroblastoma: development and place in therapy.Biologics : targets & therapy · 2019Review
- Selective targeting of IL-2 to NKG2D bearing cells for improved immunotherapy.Nature communications · 2016Article
- Enhancing Cancer Immunotherapy Via Activation of Innate Immunity.Seminars in oncology · 2015Review
- Therapeutic potential and challenges of natural killer cells in treatment of solid tumors.Frontiers in immunology · 2015Review
- NK cell-based immunotherapy for malignant diseases.Cellular & molecular immunology · 2013Review
- Enhancement of the anti-melanoma response of Hu14.18K322A by αCD40 + CpG.Cancer immunology, immunotherapy : CII · 2013Article
- Immunocytokines: a review of molecules in clinical development for cancer therapy.Clinical pharmacology : advances and applications · 2013Article
- Increasing the clinical efficacy of NK and antibody-mediated cancer immunotherapy: potential predictors of successful clinical outcome based on observations in high-risk neuroblastoma.Frontiers in pharmacology · 2012Article
- Comparison of GD2 binding capture ELISA assays for anti-GD2-antibodies using GD2-coated plates and a GD2-expressing cell-based ELISA.Journal of immunological methods · 2011Article
- Cytokines in cancer immunotherapy.Cancers · 2011Article
- The anti-tumor effect of resveratrol alone or in combination with immunotherapy in a neuroblastoma model.Cancer immunology, immunotherapy : CII · 2011Article
- Clinical cancer therapy by NK cells via antibody-dependent cell-mediated cytotoxicity.Journal of biomedicine & biotechnology · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Patients with high risk melanoma and neuroblastoma frequently experience recurrence despite surgical resection and appropriate adjuvant therapies. Immunotherapy with the immunocytokine hu14.18-IL2 (EMD-273063) was developed by means of fusion of two molecules of IL-2 to the monoclonal antibody, 14.18, that recognizes GD2, expressed on the earlier mentioned malignancies. This article will discuss the results of preclinical work using EMD-273063 therapy, including data suggesting that intratumoral therapy may have enhanced antitumor benefit compared with intravenous therapy. Initial clinical trials in adult melanoma and pediatric neuroblastoma have demonstrated acceptable toxicity profiles in dosing that induces immune activation. Preclinical and initial clinical data suggest greater efficacy in the setting of minimal residual disease; therefore, future clinical testing is planned to test the benefit of EMD-273063 in this setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.